Published in PLoS One on November 18, 2013
The causal relation between human papillomavirus and cervical cancer. J Clin Pathol (2002) 14.73
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol (2005) 9.67
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet (2009) 5.68
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med (2000) 4.73
Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol (2008) 4.30
Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ (2011) 3.90
Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst (2004) 3.11
Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ (2008) 3.08
Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis (2007) 2.93
Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis (2004) 2.77
The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine (2007) 2.55
Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis (2003) 2.06
Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol (2000) 2.00
Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol (2003) 1.96
Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine (2010) 1.94
Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine (2007) 1.71
[Cervical cancer control in Colombia: achievements and challenges of cytology based programs]. Biomedica (2008) 1.39
Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis (2008) 1.35
Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis (2009) 1.35
Prevention of cervical cancer in women with HIV. Curr Opin HIV AIDS (2009) 1.10
Treatment outcomes for squamous intraepithelial lesions. Int J Gynaecol Obstet (2000) 1.09
Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev (2010) 1.08
Health and economic impact associated with a quadrivalent HPV vaccine in Italy. Gynecol Oncol (2008) 1.06
Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination. Vaccine (2008) 0.98
A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme. Eur J Public Health (2009) 0.97
Mathematical models of cervical cancer prevention in Latin America and the Caribbean. Vaccine (2008) 0.96
Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries. Vaccine (2009) 0.91
Cost-effectiveness of conventional cytology and HPV DNA testing for cervical cancer screening in Colombia. Salud Publica Mex (2008) 0.90
Cost-effectiveness of pneumococcal conjugate vaccines of 7, 10, and 13 valences in Colombian children. Vaccine (2012) 0.88
Cost-effectiveness of different human papillomavirus vaccines in Singapore. BMC Public Health (2011) 0.85
Cervical cancer screening in high- and low-resource countries: implications and new developments. Obstet Gynecol Surv (2012) 0.83
Cost-effectiveness of the introduction of the pneumococcal polysaccharide vaccine in elderly Colombian population. Vaccine (2011) 0.82
[Following-up females having an abnormal Pap smear in Colombia]. Rev Salud Publica (Bogota) (2010) 0.82
Prevalence of infection with high-risk human papillomavirus in women in Colombia. Clin Microbiol Infect (2008) 0.77
[Quality of vaginal smear for cervical cancer screening: a concordance study]. Biomedica (2010) 0.77
[Epidemiological and economic impact of tetanus vaccination in Colombian adults]. Rev Panam Salud Publica (2011) 0.77
[Survival analysis of cervical cancer patients]. Biomedica (2009) 0.76
[Evaluating the burden of disease caused by human papillomavirus in Bogota]. Rev Salud Publica (Bogota) (2009) 0.76
Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm (2003) 3.34
Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care (2003) 2.33
Costs of necrotizing enterocolitis and cost-effectiveness of exclusively human milk-based products in feeding extremely premature infants. Breastfeed Med (2011) 2.12
Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. J Infect Dis (2013) 1.79
Wenckebach's periods or alternating Wenckebach's periods during 4:1 atrioventricular block? J Electrocardiol (2005) 1.71
Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin Infect Dis (2004) 1.65
Interactions of GIPC with dopamine D2, D3 but not D4 receptors define a novel mode of regulation of G protein-coupled receptors. Mol Biol Cell (2003) 1.47
Cost-effectiveness of primary implanted cardioverter defibrillator for sudden death prevention in congestive heart failure. Cardiovasc Drugs Ther (2004) 1.46
Where's the value in health care? Value Health (2006) 1.45
Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II. Value Health (2009) 1.43
A single cocaine exposure increases BDNF and D3 receptor expression: implications for drug-conditioning. Neuroreport (2005) 1.40
Economic impact of antidiabetic medications and glycemic control on managed care organizations: a review of the literature. J Manag Care Pharm (2006) 1.26
Striatal GPR88 expression is confined to the whole projection neuron population and is regulated by dopaminergic and glutamatergic afferents. Eur J Neurosci (2009) 1.21
Role of the dopamine D3 receptor in reactivity to cocaine-associated cues in mice. Eur J Neurosci (2002) 1.12
Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR Drug Cost Task Force report--Part VI. Value Health (2009) 1.11
Cost-effectiveness analysis of pharmaceutical care in a medicare drug benefit program. Value Health (2003) 1.09
Evaluating the cost-effectiveness of statins. J Manag Care Pharm (2004) 1.08
GIPC recruits GAIP (RGS19) to attenuate dopamine D2 receptor signaling. Mol Biol Cell (2004) 1.03
Increased dopamine D3 receptor expression accompanying behavioral sensitization to nicotine in rats. Synapse (2003) 1.03
Where do I send thee? Does physician-ownership affect referral patterns to ambulatory surgery centers? Health Aff (Millwood) (2008) 0.98
Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV. Value Health (2009) 0.98
[Validating the Epworth sleepiness scale]. Rev Salud Publica (Bogota) (2008) 0.96
Good research practices for measuring drug costs in cost effectiveness analyses: an industry perspective: the ISPOR Drug Cost Task Force report--Part V. Value Health (2009) 0.96
Understanding the underlying drivers of inpatient cost growth: a literature review. Am J Manag Care (2003) 0.96
Good research practices for measuring drug costs in cost-effectiveness analyses: a managed care perspective: the ISPOR Drug Cost Task Force report--Part III. Value Health (2009) 0.96
E-cadherin determines Caveolin-1 tumor suppression or metastasis enhancing function in melanoma cells. Pigment Cell Melanoma Res (2013) 0.95
Cervical cancer screening with naked-eye visual inspection in Colombia. Int J Gynaecol Obstet (2010) 0.94
Patterns and trends in cancer mortality in Colombia 1984-2008. Cancer Epidemiol (2013) 0.93
Effects of ambulatory-care pharmacist consultation on mortality and hospitalization. Am J Manag Care (2003) 0.91
Duration of resuscitation efforts and survival after in-hospital cardiac arrest. Lancet (2013) 0.90
Subapical localization of the dopamine D3 receptor in proximal tubules of the rat kidney. J Histochem Cytochem (2004) 0.90
CLIC6, a member of the intracellular chloride channel family, interacts with dopamine D(2)-like receptors. Brain Res Mol Brain Res (2003) 0.90
Neuroadaptations to hyperdopaminergia in dopamine D3 receptor-deficient mice. Life Sci (2004) 0.89
Brain-derived neurotrophic factor controls dopamine D3 receptor expression: therapeutic implications in Parkinson's disease. Eur J Pharmacol (2003) 0.89
Long term healthcare costs of infants who survived neonatal necrotizing enterocolitis: a retrospective longitudinal study among infants enrolled in Texas Medicaid. BMC Pediatr (2013) 0.88
Antidepressant use in geriatric populations: the burden of side effects and interactions and their impact on adherence and costs. Am J Geriatr Psychiatry (2011) 0.87
Incidence and prevalence of psoriatic arthritis in Buenos Aires, Argentina: a 6-year health management organization-based study. Rheumatology (Oxford) (2010) 0.87
The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States. Neuro Oncol (2013) 0.87
Direct and indirect interactions of the dopamine D₃ receptor with glutamate pathways: implications for the treatment of schizophrenia. Naunyn Schmiedebergs Arch Pharmacol (2012) 0.86
Comparative effectiveness of statin plus fibrate combination therapy and statin monotherapy in patients with type 2 diabetes: use of propensity-score and instrumental variable methods to adjust for treatment-selection bias. Pharmacoepidemiol Drug Saf (2012) 0.85
Costs and benefits of male circumcision. JAMA Pediatr (2013) 0.85
[Child mortality from cancer in Colombia, 1985-2008]. Rev Panam Salud Publica (2011) 0.84
Reliability and validity of a new survey to assess global health competencies of health professionals. Glob J Health Sci (2012) 0.84
Brain-derived neurotrophic factor and the plasticity of the mesolimbic dopamine pathway. Int Rev Neurobiol (2004) 0.83
Asthma costs and utilization in a managed care organization. J Allergy Clin Immunol (2008) 0.83
Role of DRD3 in morphine-induced conditioned place preference using drd3-knockout mice. Neuroreport (2004) 0.81
Effects of combined ketamine/xylazine anesthesia on light induced retinal degeneration in rats. PLoS One (2012) 0.81
Potential epidemiological and economical impact of two rotavirus vaccines in Colombia. Vaccine (2010) 0.81
Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States. Pharmacoeconomics (2013) 0.80
HPV prevalence in Colombian women with cervical cancer: implications for vaccination in a developing country. Infect Dis Obstet Gynecol (2009) 0.79
Appropriate econometric methods for pharmacoeconometric studies of retrospective claims data: an introductory guide. J Manag Care Pharm (2005) 0.79
Brain-derived neurotrophic factor controls dopamine D3 receptor expression: implications for neurodevelopmental psychiatric disorders. Neurotox Res (2003) 0.79
IGF1R gene expression as a predictive marker of response to ionizing radiation for patients with locally advanced HPV16-positive cervical cancer. Anticancer Res (2012) 0.79
[Endemic tendencies and bacterial resistance markers in third-level hospitals in Bogotá, Colombia]. Rev Salud Publica (Bogota) (2006) 0.79
A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Opin Pharmacother (2007) 0.79
Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis. Expert Rev Pharmacoecon Outcomes Res (2015) 0.79
Cost-benefit analysis of in-hospital influenza vaccination of postpartum women. Obstet Gynecol (2012) 0.78
The cost-effectiveness of open or thoracoscopic thymectomy compared to medical treatment in managing Myasthenia gravis without thymomas. Rev Salud Publica (Bogota) (2012) 0.78
Perception of the usefulness of drug/gene pairs and barriers for pharmacogenomics in Latin America. Curr Drug Metab (2014) 0.78
Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer. Cancer (2009) 0.78
[Attitudes of personnel monitoring intra-hospital adverse events in Colombia]. Rev Salud Publica (Bogota) (2009) 0.77
[Epidemiological and economic impact of tetanus vaccination in Colombian adults]. Rev Panam Salud Publica (2011) 0.77
[Incidence and preventability of adverse events in patients hospitalised in three Colombian hospitals during 2006]. Rev Salud Publica (Bogota) (2008) 0.77
[Economic evaluation of influenza vaccine applied to health personnel attending hospitalised oncological patients]. Rev Salud Publica (Bogota) (2009) 0.77
Efficacy of bypassing agents in patients with hemophilia and inhibitors: a systematic review and meta-analysis. Clin Ther (2012) 0.77
Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine. CNS Drugs (2005) 0.76
Harms C1-C2 instrumentation technique: anatomo-surgical guide. Spine (Phila Pa 1976) (2011) 0.76
2-Methoxyestradiol inhibits progesterone-dependent tissue factor expression and activity in breast cancer cells. Horm Cancer (2010) 0.76
Adverse events and intravenous versus oral bisphosphonate use in patients with osteoporosis and cancer in the U.S. Gen Dent (2010) 0.76
Illicit drug use in seven Latin American countries: critical perspectives of families and familiars. Rev Lat Am Enfermagem (2009) 0.76
Incremental expenditure of biologic disease modifying antirheumatic treatment using instrumental variables in panel data. Health Econ (2012) 0.76
Comparing patient access to pharmaceuticals in the UK and US. Appl Health Econ Health Policy (2006) 0.75
Effects of medicaid on clinical outcomes. N Engl J Med (2013) 0.75
Expensive conditions. Health Aff (Millwood) (2002) 0.75
The evidence that shows that stroke and cesarean section are associated needs to be critically reviewed. Am J Obstet Gynecol (2008) 0.75
A six-year study of diagnostic lower extremity imaging practice patterns and outcomes in the Veterans Affairs health care system. Int J Angiol (2008) 0.75
What is more valuable: fenofibrate patents or fenofibrate clinical outcomes? Arch Intern Med (2012) 0.75
Muscle magnetic resonance imaging and histopathology in ACTA1-related congenital nemaline myopathy. Muscle Nerve (2014) 0.75
Considering health equity when moving from evidence-based guideline recommendations to implementation: a case study from an uppermiddle income country on the GRADE approach. Health Policy Plan (2017) 0.75
Cost effectiveness of diagnostic laparoscopy in reproductive aged females suffering from non-specific acute low abdominal pain. Rev Salud Publica (Bogota) (2005) 0.75
Inequalities in prescription of hydrochlorothiazide for diabetic hypertensive patients in Colombia. Rev Salud Publica (Bogota) (2011) 0.75
[Economic impact of pneumococcal vaccine on oncological patients]. Rev Salud Publica (Bogota) (2007) 0.75
Risk of all-cause hospitalization in COPD patients initiating long-acting or short-acting beta agonist therapy. J Med Econ (2013) 0.75
Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-β1a in relapsing-remitting multiple sclerosis. CNS Drugs (2015) 0.75
Cost-benefit analysis of hospital based postpartum vaccination with combined tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap). Vaccine (2013) 0.75
Novel methods of measuring clinical outcomes from psoriasis and psoriatic arthritis clinical trials. Expert Rev Pharmacoecon Outcomes Res (2014) 0.75
[Models used for decision-making in health care]. Rev Salud Publica (Bogota) (2008) 0.75
[Resistance to cefepime in Enterobacter cloacae isolates from hospitals in Bogotá, Colombia]. Rev Salud Publica (Bogota) (2006) 0.75
Experts' clinical diagnosis test as a gold standard for cephalometric evaluation of vertical facial excess. Rev Salud Publica (Bogota) (2007) 0.75
A review of the economic burden of glioblastoma and the cost effectiveness of pharmacologic treatments. Pharmacoeconomics (2014) 0.75
Factors Associated with Failure to Achieve SVR in Hepatitis C Genotype 3 Patients Within an Integrated Care Delivery System. J Manag Care Spec Pharm (2015) 0.75
The Surgeon Volume-outcome Relationship: Not Yet Ready for Policy. Ann Surg (2017) 0.75
Effects of Increasing Airway Pressures on the Pressure of the Endotracheal Tube Cuff During Pelvic Laparoscopic Surgery. Anesth Analg (2017) 0.75